Answers are grounded in this paper and cite their sources.
Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context.
No takes yet. Share an insight, caveat, or question.
Fliers et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: